{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:28:29Z","timestamp":1791912509799,"version":"4.3.4"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T00:00:00Z","timestamp":1646352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["XXZ0302"],"award-info":[{"award-number":["XXZ0302"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009601","name":"Beijing Municipal Administration of Hospitals","doi-asserted-by":"publisher","award":["XXT28"],"award-info":[{"award-number":["XXT28"]}],"id":[{"id":"10.13039\/501100009601","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["XMLX202127"],"award-info":[{"award-number":["XMLX202127"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009331","name":"Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support","doi-asserted-by":"publisher","award":["XMLX 201706"],"award-info":[{"award-number":["XMLX 201706"]}],"id":[{"id":"10.13039\/501100009331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX10203202 -003"],"award-info":[{"award-number":["2017ZX10203202 -003"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX10201201-001-006"],"award-info":[{"award-number":["2017ZX10201201-001-006"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2017ZX10201201-002-006"],"award-info":[{"award-number":["2017ZX10201201-002-006"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z151100004015122"],"award-info":[{"award-number":["Z151100004015122"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["D161100002716002"],"award-info":[{"award-number":["D161100002716002"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Virologica Sinica"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.virs.2022.03.001","type":"journal-article","created":{"date-parts":[[2022,3,4]],"date-time":"2022-03-04T12:40:25Z","timestamp":1646397625000},"page":"390-397","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients"],"prefix":"10.1016","volume":"37","author":[{"given":"Minghui","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjie","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4108-7037","authenticated-orcid":false,"given":"Wei","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5622-1959","authenticated-orcid":false,"given":"Yao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.virs.2022.03.001_bib1","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.cgh.2019.07.018","article-title":"Durability of spontaneous and treatment-related loss of hepatitis B s antigen","volume":"18","author":"Alawad","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2022.03.001_bib2","first-page":"1","article-title":"Abstracts of the 26th annual conference of APASL, February 15-19, 2017, Shanghai, China","volume":"11","year":"2017","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virs.2022.03.001_bib3","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3851\/IMP1497","article-title":"Hepatitis B surface antigen seroclearance during chronic HBV infection","volume":"15","author":"Chu","year":"2010","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.virs.2022.03.001_bib4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1093\/cid\/cir755","article-title":"Prevalence of and risk factors for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers","volume":"54","author":"Chu","year":"2012","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.virs.2022.03.001_bib5","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2022.03.001_bib6","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3390\/v11010078","article-title":"Naturally occurring mutations within HBV surface promoter II sequences affect transcription activity, HBsAg and HBV DNA levels in HBeAg-positive chronic hepatitis B patients","volume":"11","author":"Hao","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.virs.2022.03.001_bib7","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1016\/j.imbio.2014.07.020","article-title":"Hepatitis B virus e antigen (HBeAg) may have a negative effect on dendritic cell generation","volume":"219","author":"Hatipoglu","year":"2014","journal-title":"Immunobiology"},{"key":"10.1016\/j.virs.2022.03.001_bib8","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1111\/j.1537-2995.2008.01701.x","article-title":"Hepatitis B virus infection and transfusion medicine: science and the occult","volume":"48","author":"Hollinger","year":"2008","journal-title":"Transfusion"},{"key":"10.1016\/j.virs.2022.03.001_bib9","doi-asserted-by":"crossref","first-page":"10412","DOI":"10.1128\/JVI.00111-14","article-title":"Downregulation of interleukin-18-mediated cell signaling and interferon gamma expression by the hepatitis B virus e antigen","volume":"88","author":"Jegaskanda","year":"2014","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.virs.2022.03.001_bib10","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.virs.2022.03.001_bib11","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12250-020-00290-7","article-title":"Early serum HBsAg kinetics as predictor of HBsAg loss in patients with HBeAg-negative chronic hepatitis B after treatment with pegylated interferon\u03b1-2a","volume":"36","author":"Li","year":"2021","journal-title":"Virol. Sin."},{"key":"10.1016\/j.virs.2022.03.001_bib12","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1002\/jmv.26301","article-title":"Association of cytokines with hepatitis B virus and its antigen","volume":"92","author":"Li","year":"2020","journal-title":"J.\u00a0Med. Virol."},{"key":"10.1016\/j.virs.2022.03.001_bib13","first-page":"443","article-title":"Changes in the cytokine profiles of patients with chronic hepatitis B during antiviral therapy","volume":"34","author":"Li","year":"2021","journal-title":"Biomed. Environ. Sci."},{"key":"10.1016\/j.virs.2022.03.001_bib14","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1007\/s00705-021-05062-6","article-title":"Transforming growth factor \u03b2 as a possible independent factor in chronic hepatitis B","volume":"166","author":"Li","year":"2021","journal-title":"Arch. Virol."},{"issue":"Suppl. 1","key":"10.1016\/j.virs.2022.03.001_bib15","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/jvh.13151","article-title":"Predictors of sustained functional cure in hepatitis B envelope antigen-negative patients achieving hepatitis B surface antigen seroclearance with interferon-alpha-based therapy","volume":"26","author":"Li","year":"2019","journal-title":"J.\u00a0Viral Hepat."},{"key":"10.1016\/j.virs.2022.03.001_bib16","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.4103\/0366-6999.211541","article-title":"Ratios of T-helper 2 cells to T-helper 1 cells and cytokine levels in patients with hepatitis B","volume":"130","author":"Li","year":"2017","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.virs.2022.03.001_bib17","first-page":"177","article-title":"The predictive value of baseline HBsAg level and early response for HBsAg loss in patients with HBeAg-positive chronic hepatitis B during pegylated interferon alpha-2a treatment","volume":"30","author":"Li","year":"2017","journal-title":"Biomed. Environ. Sci."},{"key":"10.1016\/j.virs.2022.03.001_bib18","doi-asserted-by":"crossref","first-page":"43","DOI":"10.4103\/0366-6999.221275","article-title":"Plasmacytoid dendritic cell function and cytokine network profiles in patients with acute or chronic hepatitis B virus infection","volume":"131","author":"Li","year":"2018","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.virs.2022.03.001_bib19","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1093\/infdis\/jiv547","article-title":"Peginterferon is superior to nucleos(t)ide analogues for prevention of hepatocellular carcinoma in chronic hepatitis B","volume":"213","author":"Liang","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.virs.2022.03.001_bib20","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of Tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.virs.2022.03.001_bib21","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1872-034X.2007.00094.x","article-title":"Low serum level of hepatitis B core-related antigen indicates unlikely reactivation of hepatitis after cessation of lamivudine therapy","volume":"37","author":"Matsumoto","year":"2007","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.virs.2022.03.001_bib22","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1872-034X.2011.00910.x","article-title":"Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B","volume":"42","author":"Matsumoto","year":"2012","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.virs.2022.03.001_bib23","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00535-017-1360-z","article-title":"Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue\/peg-interferon sequential therapy","volume":"53","author":"Matsumoto","year":"2018","journal-title":"J.\u00a0Gastroenterol."},{"key":"10.1016\/j.virs.2022.03.001_bib24","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.01.016","article-title":"High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study","volume":"50","author":"Moucari","year":"2009","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2022.03.001_bib25","series-title":"Hepatitis B (Chronic): Diagnosis and Management of Chronic Hepatitis B in Children, Young People and Adults","article-title":"National Institute for health and Care excellence: clinical guidelines","author":"National Clinical Guideline","year":"2013"},{"key":"10.1016\/j.virs.2022.03.001_bib26","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s12072-017-9799-9","article-title":"Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update","volume":"11","author":"Omata","year":"2017","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virs.2022.03.001_bib27","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1111\/liv.14801","article-title":"Outcome of Chinese patients with hepatitis B at 96 weeks after functional cure with IFN versus combination regimens","volume":"41","author":"Pan","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.virs.2022.03.001_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.7150\/ijms.2.36","article-title":"Natural history and clinical consequences of hepatitis B virus infection","volume":"2","author":"Pan","year":"2005","journal-title":"Int. J. Med. Sci."},{"key":"10.1016\/j.virs.2022.03.001_bib29","first-page":"21","article-title":"Transcriptional control of hepadnavirus gene expression","volume":"168","author":"Schaller","year":"1991","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.virs.2022.03.001_bib30","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1128\/MMBR.64.1.51-68.2000","article-title":"Hepatitis B virus biology","volume":"64","author":"Seeger","year":"2000","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"10.1016\/j.virs.2022.03.001_bib31","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.3855\/jidc.11447","article-title":"Mutations in reverse transcriptase region of HBV affect Hepatitis B surface antigen titers and its correlation with HBV DNA","volume":"13","author":"Shen","year":"2019","journal-title":"J.\u00a0Infect. Dev. Ctries."},{"key":"10.1016\/j.virs.2022.03.001_bib32","doi-asserted-by":"crossref","first-page":"8238","DOI":"10.1016\/j.vaccine.2020.09.083","article-title":"Epidemiological distribution of hepatitis B virus genotypes in 1-29-year-olds in the mainland of China","volume":"38","author":"Su","year":"2020","journal-title":"Vaccine"},{"key":"10.1016\/j.virs.2022.03.001_bib33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.virs.2022.03.001_bib34","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/apt.14577","article-title":"An expert consensus for the management of chronic hepatitis B in Asian Americans","volume":"47","author":"Tong","year":"2018","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.virs.2022.03.001_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s12072-014-9571-3","article-title":"How to achieve immune control in chronic hepatitis B?","volume":"9","author":"van Campenhout","year":"2015","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.virs.2022.03.001_bib36","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.cgh.2019.04.020","article-title":"Durability of interferon-induced hepatitis B surface antigen seroclearance","volume":"18","author":"Wu","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.virs.2022.03.001_bib37","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2017.09.018","article-title":"Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients","volume":"68","author":"Yip","year":"2017","journal-title":"J.\u00a0Hepatol."},{"key":"10.1016\/j.virs.2022.03.001_bib38","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.antiviral.2006.05.006","article-title":"Hepatitis B virus e antigen production is dependent upon covalently closed circular (ccc) DNA in HepAD38 cell cultures and may serve as a cccDNA surrogate in antiviral screening assays","volume":"72","author":"Zhou","year":"2006","journal-title":"Antivir. Res."}],"container-title":["Virologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X22000554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1995820X22000554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T08:38:31Z","timestamp":1778834311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1995820X22000554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S1995820X22000554"],"URL":"https:\/\/doi.org\/10.1016\/j.virs.2022.03.001","relation":{},"ISSN":["1995-820X"],"issn-type":[{"value":"1995-820X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consolidation treatment needed for sustained HBsAg-negative response induced by interferon-alpha in HBeAg positive chronic hepatitis B patients","name":"articletitle","label":"Article Title"},{"value":"Virologica Sinica","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.virs.2022.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}]}}